Table 3 Ongoing prospective studies, evaluating new hormonal therapies in black populations
From: A review of new hormonal therapies for prostate cancer in black men: is there enough data?
Trial (NCT) | Study design | Treatment | Population | Number of patients (N) |
|---|---|---|---|---|
Phase I | Abiraterone | mCRPC | 10 | |
Phase II | Abiraterone or Enzalutamide + Avelumab | mCRPC | 27 | |
Phase II | Abiraterone | mCRPC | 50 | |
Phase II | Abiraterone + Apalutamide | mCRPC | 50 |